Does the leucodepletion process mean that there will no longer be a need for CMV negative blood components?
Leucocyte depleted components are considered to offer a high level of safety in preventing CMV transmission, but are not universally believed to be equivalent to CMV-seronegative components. For indications where CMV negative blood components are required, the following is recommended: 1. Select CMV-seronegative components whenever possible. 2. If not available, leucocyte depleted components are considered to offer a high level of safety in preventing CMV transmission, but are not universally believed to be equivalent to CMV-seronegative components. 3. Careful monitoring for CMV infection and disease in high risk patients. The additional benefit of leucocyte depletion in preventing transfusion transmitted CMV infection, in the context of the sole use of CMV-seronegative components, is unknown.
Related Questions
- Does the leucodepletion process mean that there will no longer be a need for CMV negative blood components?
- Will the leucodepletion process mean it will take longer for the Blood Service to issue each component?
- Will the leucodepletion process mean it will take longer for ARCBS to issue each component?
